Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.67 Average Target Price from Brokerages

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been given a consensus rating of “Moderate Buy” by the five analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $28.6667.

A number of equities analysts have issued reports on KYTX shares. Morgan Stanley set a $33.00 price target on Kyverna Therapeutics in a research note on Monday, December 15th. HC Wainwright increased their target price on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a report on Monday, October 27th. Wells Fargo & Company boosted their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday.

Kyverna Therapeutics Stock Down 6.7%

Shares of NASDAQ KYTX opened at $8.77 on Thursday. The company’s fifty day simple moving average is $7.81 and its 200 day simple moving average is $5.60. Kyverna Therapeutics has a 12-month low of $1.78 and a 12-month high of $13.67. The firm has a market cap of $384.13 million, a PE ratio of -2.35 and a beta of 3.45.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.12. On average, equities analysts predict that Kyverna Therapeutics will post -3.29 earnings per share for the current year.

Insider Transactions at Kyverna Therapeutics

In other news, Director Beth C. Seidenberg bought 133,333 shares of the stock in a transaction on Thursday, December 18th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $999,997.50. Following the completion of the purchase, the director directly owned 869,317 shares in the company, valued at $6,519,877.50. This represents a 18.12% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Karen Marie Walker sold 23,998 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the transaction, the chief technology officer directly owned 22,636 shares in the company, valued at $276,159.20. This represents a 51.46% decrease in their position. The disclosure for this sale is available in the SEC filing. 22.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kyverna Therapeutics

Several hedge funds have recently made changes to their positions in KYTX. Vanguard Group Inc. grew its position in Kyverna Therapeutics by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after acquiring an additional 9,858 shares in the last quarter. Insight Holdings Group LLC lifted its stake in Kyverna Therapeutics by 8.3% during the first quarter. Insight Holdings Group LLC now owns 989,054 shares of the company’s stock worth $1,909,000 after purchasing an additional 76,139 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Kyverna Therapeutics by 21.9% in the 3rd quarter. Millennium Management LLC now owns 551,635 shares of the company’s stock worth $3,310,000 after purchasing an additional 99,075 shares in the last quarter. Kera Capital Partners Inc. boosted its holdings in shares of Kyverna Therapeutics by 12.2% in the 2nd quarter. Kera Capital Partners Inc. now owns 421,924 shares of the company’s stock worth $1,295,000 after purchasing an additional 45,738 shares in the last quarter. Finally, Woodline Partners LP bought a new position in shares of Kyverna Therapeutics during the 3rd quarter valued at about $1,513,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.